Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Taken together, the fourth-generation nanobody-derived anti-CD5 CAR-NK cells may be a promising therapeutic against T-cell malignancies.
Authors
- Yingling Zu (ORCID: https://orcid.org/0000-0001-5537-0357)
- Qiumei Lu (ORCID: https://orcid.org/0000-0003-3607-7141)
- Hongchang Su
- Jian Zhou (ORCID: https://orcid.org/0000-0001-9712-6301)
- Quan Ren
- Yongping Song (ORCID: https://orcid.org/0000-0003-4191-0548)
- Jishuai Zhang
Institutions
- Zhengzhou University (CN)
- Shenzhen Bioeasy Biotechnology (China) (CN)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1186/s40164-024-00577-5
- Citations
- 12
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.39
Funders
- Science and Technology Planning Project of Shenzhen Municipality